Klotho Neurosciences, Inc. (KLTO) - Net Assets
Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) has net assets worth $9.93 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.07 Million) and total liabilities ($145.89K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read KLTO total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.93 Million |
| % of Total Assets | 98.55% |
| Annual Growth Rate | 4.92% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 65.14 |
Klotho Neurosciences, Inc. - Net Assets Trend (2021–2024)
This chart illustrates how Klotho Neurosciences, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore total assets of Klotho Neurosciences, Inc. for the complete picture of this company's asset base.
Annual Net Assets for Klotho Neurosciences, Inc. (2021–2024)
The table below shows the annual net assets of Klotho Neurosciences, Inc. from 2021 to 2024. For live valuation and market cap data, see KLTO company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.19 Million | +107.33% |
| 2023-12-31 | $571.72K | -51.52% |
| 2022-12-31 | $1.18 Million | +14.89% |
| 2021-12-31 | $1.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Klotho Neurosciences, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 794517300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.71K | 0.23% |
| Other Components | $11.75 Million | 990.89% |
| Total Equity | $1.19 Million | 100.00% |
Klotho Neurosciences, Inc. Competitors by Market Cap
The table below lists competitors of Klotho Neurosciences, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kleannara
KO:004540
|
$50.60 Million |
|
Union Materials Corp
KO:047400
|
$50.61 Million |
|
Hanwha Chemical Corp Pref
KO:009835
|
$50.61 Million |
|
Kervansaray Yatirim Holding AS
IS:KERVN
|
$50.62 Million |
|
Dc Infotech And Communication Limited
NSE:DCI
|
$50.58 Million |
|
Bizim Toptan Satis Magazalari AS
IS:BIZIM
|
$50.58 Million |
|
CTK Co. Ltd
KQ:260930
|
$50.57 Million |
|
Leviathan Gold Ltd
V:LVX
|
$50.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Klotho Neurosciences, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 571,717 to 1,185,345, a change of 613,628 (107.3%).
- Net loss of 6,150,372 reduced equity.
- Share repurchases of 120,000 reduced equity.
- New share issuances of 295,000 increased equity.
- Other factors increased equity by 6,589,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.15 Million | -518.87% |
| Share Repurchases | $120.00K | -10.12% |
| Share Issuances | $295.00K | +24.89% |
| Other Changes | $6.59 Million | +555.87% |
| Total Change | $- | 107.33% |
Book Value vs Market Value Analysis
This analysis compares Klotho Neurosciences, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 476.43x to 7.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.00 | $0.47 | x |
| 2022-12-31 | $0.00 | $0.47 | x |
| 2023-12-31 | $0.00 | $0.47 | x |
| 2024-12-31 | $0.06 | $0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Klotho Neurosciences, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -518.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.07x
- Recent ROE (-518.87%) is below the historical average (-200.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -108.05% | 0.00% | 0.00x | 1.01x | $-1.21 Million |
| 2022 | -50.76% | 0.00% | 0.00x | 2.15x | $-716.51K |
| 2023 | -123.74% | 0.00% | 0.00x | 3.84x | $-764.63K |
| 2024 | -518.87% | 0.00% | 0.00x | 2.07x | $-6.27 Million |
Industry Comparison
This section compares Klotho Neurosciences, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Klotho Neurosciences, Inc. (KLTO) | $9.93 Million | -108.05% | 0.01x | $50.59 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more